Abstract Number: 524 • 2012 ACR/ARHP Annual Meeting
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts in Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. SS…Abstract Number: 525 • 2012 ACR/ARHP Annual Meeting
Gene Expression Profiling in a Large Cohort of Europeans with Sjögren’s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways
Background/Purpose: Sjögren’s syndrome (SS), characterized by lymphocytic infiltration of exocrine glands, is a progressive autoimmune exocrinopathy present in 0.7-1% of Europeans. To better understand the…Abstract Number: 526 • 2012 ACR/ARHP Annual Meeting
Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjogren’s Syndrome Salivary Glands
Background/Purpose: Salivary glands are a prominent target organ in Sjögren’s syndrome (SS), with patients having abnormal secretory function and inflammatory infiltration of these glands. Little…Abstract Number: 527 • 2012 ACR/ARHP Annual Meeting
Multiplexed Nanostring Screening for Salivary Gland Viral Elements in Sjogren’s Syndrome
Background/Purpose: To test the hypothesis that viruses are associated with Sjogren’s syndrome, salivary gland RNA extracts from Sjogren’s patients and non-Sjogren’s controls were screened for…Abstract Number: 528 • 2012 ACR/ARHP Annual Meeting
Mxa As a Biomarker for Systemic Interferon Type I Activation in Primary Sjögren′s Syndrome
Background/Purpose: To establish an easy and practical assay for detection of systemic Interferon (IFN) type I activation in primary Sjögren's syndrome (pSS). The monocyte IFN…Abstract Number: 529 • 2012 ACR/ARHP Annual Meeting
The Axis P2X7 Receptor-Inflammasome: A Role in Modulating Inflammatory Response in Primary Sjögren’s Syndrome?
Background/Purpose: The exact cause of exocrine gland dysfunction in primary Sjögren’s syndrome (pSS) has not been fully delineated, but it is thought that both innate…Abstract Number: 490 • 2012 ACR/ARHP Annual Meeting
12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the…Abstract Number: 491 • 2012 ACR/ARHP Annual Meeting
Predictors of Initiating Biologic Monotherapy in Biologic Naïve Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Background/Purpose: Published data have shown that approximately one-third of patients with RA are treated with biologic (Bio) monotherapy (MT) (without concomitant DMARD) and a considerable…Abstract Number: 492 • 2012 ACR/ARHP Annual Meeting
Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events
Background/Purpose: There are currently five anti-TNF agents that have been approved for various autoimmune illnesses. There is no convincing evidence that any one of these…Abstract Number: 493 • 2012 ACR/ARHP Annual Meeting
Effect of Infliximab On Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with significant functional impairment and work disability. In the absence of treatment, approximately 80% of…Abstract Number: 494 • 2012 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
Background/Purpose: The prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men depending on age. Furthermore, in women RA incidence increases…Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…Abstract Number: 496 • 2012 ACR/ARHP Annual Meeting
Real-World Effectiveness of Infliximab in Improving Routine Assessment of Patient Index Data 3 Outcomes: The Canadian Experience
Background/Purpose: The routine assessment of patient index data 3 (RAPID3) was recently designed as a pooled index of 3 patient-reported outcomes (PROs): physical function, pain…Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…Abstract Number: 498 • 2012 ACR/ARHP Annual Meeting
LIGHT (TNFSF14), Cathepsin-K, DKK-1 and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling
Background/Purpose: We previously reported increased expression of cell membrane RANKL in PBMC of patients with active rheumathoid arthritis (RA) which was down-regulated by anti TNF-α…